S

Smith+Nephew

Global medical devices for orthopedics

ENT Sales Representative - ENT

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Bachelor of Arts (BA), Bachelor of Science (BS)
Dallas, TX, USA
In PersonTravel within the designated sales territory, including 2–4 overnights per month; infrequent national travel for events and conferences.
Sales & Account ManagementField Sales

About the job

Requirements
  • A BA or BS degree, or equivalent work experience, is required.
  • Two to four years of direct sales experience is required; medical or hospital environment sales is preferred.
  • Demonstrated success in achieving quota year over year is required.
  • The candidate must be able to demonstrate resilience and determination in difficult and complex selling environments.
  • The candidate must have expertise in ENT products, including product technical features, clinical basis for use, and competitive advantages and disadvantages compared with products and modalities currently in use.
  • The candidate must understand relevant anatomy, surgical techniques, product advantages, and product limitations to serve as a resource and consultant in clinical environments.
  • The candidate must be able to digest clinical data and communicate it effectively to a surgical audience.
  • The candidate must be able to integrate Smith+Nephew's sales model, including Challenger, with their existing selling style and experience.
  • The candidate must be able to manage sales opportunities from identification through closing, maintenance, and growth.
  • The candidate must be able to navigate hospital purchasing processes and have experience successfully selling into integrated delivery networks where needed.
  • The candidate must understand customer businesses and present solutions aligned with their business goals.
  • The candidate must have a basic understanding of reimbursement components and cycles to guide customers to appropriate support resources.
  • The candidate must be organized, manage time effectively, and balance field and administrative work.
  • The candidate must complete the credentialing process required for entry into healthcare facilities, which often includes COVID-19 vaccine management.
Responsibilities
  • Exceed the assigned territory sales quota annually and grow the collective ENT business within a defined geographical area by selling Smith+Nephew ENT products and services.
  • Target and onboard competitive customers, introduce new therapies across various sites of care, and understand the economic environment in which customers make buying decisions.
  • Formulate and communicate mutually beneficial strategies to potential customers.
  • Build the territory customer base by converting surgeons from competitive products using company clinical, marketing, sales, and reporting tools to support customer conversion.
  • Protect current business and maintain accounts on a regular cycle.
  • Conduct annual business reviews with customers and, at minimum, quarterly analysis and calibration of the territory business plan with the Director of Sales to minimize erosion and competitive losses.
  • Identify opportunities to expand use of ENT products with current and new surgeons within active accounts.
  • Provide knowledgeable clinical support and consultation regarding ENT products, relevant anatomy, surgical techniques, and product use.
  • Support cases in awake patient environments when needed.
  • Provide peers, management, and marketing with support as needed in a team environment.
  • Travel within the designated sales territory, including two to four overnight trips per month, and travel nationally infrequently for events and conferences.
Desired Qualifications
  • Experience in medical or hospital environment sales is preferred.
  • Experience clinically supporting cases in awake patient environments is preferred.

About the company

Smith+Nephew is a global medical technology company that designs and makes medical devices for orthopaedics, sports medicine, and advanced wound care. Its products help surgeons treat joints and soft tissues and support patient recovery, including knee repair systems, single-use negative pressure wound therapy devices, and other extremity orthopaedic products. These devices are used in hospitals and clinics to perform procedures and support healing, often after surgery or injury. The company differentiates itself with a broad, worldwide product portfolio and collaborations with healthcare organizations to improve care and efficiency for patients and providers. Its goal is to improve patient outcomes, streamline medical procedures, and expand access to advanced medical solutions around the world.

Company Size

10,001+

Company Stage

IPO

Headquarters

Watford, United Kingdom

Founded

1856

Get referred to Smith+Nephew

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue reached $1.5 billion, and full-year guidance stayed intact on May 6.
  • New launches in 2026 include CORI XT, FLOW FLEXTEND, and ALLEVYN COMPLETE CARE.
  • August 2026 H1 results showed 4.6% growth, $200 million efficiency savings, and $500 million buyback.

What critics are saying

  • Reuters on August 4, 2026 cut revenue guidance to around 4% after weak U.S. knees.
  • Smith+Nephew’s finance chief John Rogers exits September 30, 2026, creating leadership churn.
  • A March 2026 humeral nail recall and older hip litigation expose recurring quality risk.

What makes Smith+Nephew unique

  • Smith+Nephew’s CORI XT robotics spans knee, shoulder, and future hip workflows.
  • Its ASC Solutions bundles facility design, financing, and clinical enablement for outpatient surgery.
  • ALLEVYN, RENASYS, and LEAF create a broad wound-care platform with measurable outcomes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Holidays
  • Flexible Work Hours
  • Parental Leave
  • Fertility Treatment Support
  • Family Planning Benefits
  • Tuition Reimbursement

Company News

Yahoo Finance
Oct 18th, 2026
Three undervalued UK stocks for October 2026: Morgan Sindall, Shell, Smith & Nephew

Simply Wall St has named three London-listed stocks it says trade below estimated fair value based on future cash flows: Morgan Sindall Group, Shell, and Smith & Nephew. The screen flags 23 more companies not covered. Morgan Sindall Group, a £1.8b construction and regeneration firm, saw its secured order book rise 39% to £12bn. Its Partnership Housing arm ties it to long-term contracts, though policy changes and planning delays pose risks. Shell has a market value of about £225.1b and revenue of $443.2b. Its LNG portfolio exceeds 60 million tons. Smith & Nephew, valued at £9.1b, relies on repeat implant procedures. New products drove 75% of first-half growth.

Yahoo Finance
Oct 6th, 2026
Smith+Nephew launches CARTIHEAL AGILI-C cartilage repair implant in Europe

Smith+Nephew has launched its CARTIHEAL AGILI-C Cartilage Repair Implant in Europe. The product, already introduced in the US during 2024, will be featured at the International Cartilage Regeneration & Joint Preservation Society Summit in Porto, Portugal from 8-10 October. The implant, composed of aragonite (a naturally occurring calcium carbonate), acts as a biphasic scaffold to repair cartilage, restore bone and relieve pain. A recent study published in the American Journal of Sports Medicine showed the implant resulted in higher overall Knee injury and Osteoarthritis Outcome Scores versus surgical standard of care for all time points out to 60 months. The implant will initially launch in twelve countries including Austria, Belgium, France, Germany, Ireland, Italy, Luxembourg, Netherlands, Portugal, Spain, Switzerland and the UK.

Kalkine Media
Sep 10th, 2026
Smith+Nephew issues $700M 5.750% bonds due 2036 to refinance 2030 senior notes

Smith & Nephew has issued $700 million in senior notes with a 5.750% coupon maturing in 2036, netting $690.9 million after underwriting fees. The FTSE 100 medical technology firm will primarily use proceeds to fund a tender offer for its existing 2.032% senior notes due 2030, with remaining funds allocated to general corporate purposes. The refinancing replaces lower-yield debt with higher-coupon notes, reflecting current credit market conditions. BofA Securities, J.P. Morgan Securities, Mizuho Securities USA, and SMBC Nikko Securities America managed the transaction, which closed on 11 September 2026. Founded in Hull in 1856, Smith & Nephew operates across orthopaedics, sports medicine, ENT, and advanced wound management. The company employs approximately 17,000 people across 100 countries and reported annual sales of $6.2 billion in 2025.

Ticker Report
Sep 3rd, 2026
Corient Private Wealth LP Makes New $2 Million Investment in Smith & Nephew SNATS, Inc. $SNN

Corient Private Wealth LP purchased a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 31,871 shares of the medical equipment provider’s stock, valued at approximately $1,999,000. Other large investors […]

Yahoo Finance
Aug 17th, 2026
Smith+Nephew launches FLOW FLEXTEND COBLATION Wand with adjustable-angle tip for complex hip procedures

Smith+Nephew has launched the FLOW FLEXTEND COBLATION Wand, a new radiofrequency resection device designed for complex hip procedures. The device features an adjustable-angle tip that provides enhanced joint access and tissue targeting in difficult-to-reach hip, knee, and shoulder anatomies. The wand incorporates Smith+Nephew's FLOW~IQ technology, which automatically balances saline outflow with COBLATION energy. Its design includes a precision electrode with an adjustable tip that improves access to targeted tissues whilst facilitating insertion and removal. The angle adjustment mechanism allows surgeons to set the desired position without continuous manual control. Early surgeon feedback has been positive, with users highlighting improved versatility in the central compartment and precise tissue preservation capabilities compared to existing instruments.